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Nanospheres are being developed for the oral delivery of
peptide-based drugs such as insulin. Mucoadhesive, biodegradable,
biocompatible, and acid-protective biomaterials are described us-
ing a combination of natural polyelectrolytes, with particles for-
mulated through nanoemulsion dispersion followed by triggered
in situ gel complexation. Biomaterials meeting these criteria include
alginate, dextran, chitosan, and albumin in which alginate/dextran
forms the core matrix complexed with chitosan and albumin coat.
Smaller size and higher albumin-based acid-protective formulation
was orally administered to diabetic rats and glucose reduction and
physiological response analyzed. Insulin encapsulation efficiency
was 90, 82, and 66% for uncoated, chitosan-coated, and albumin-
chitosan-coated alginate nanospheres, respectively. The choice of
coating polymer seems to influence insulin release profile and to
be crucial to prevent peptic digestion. Physiological response fol-
lowing oral delivery showed that insulin albumin-chitosan-coated
alginate nanospheres reduced glycemia ∼72% of basal values. Al-
bumin serves as an important enteric coating providing acid- and
protease protection enabling uptake of active drug following oral
dosage.
Keywords Nanospheres, Insulin, Polyelectrolyte complexes, Oral
Delivery
Diabetes mellitus type 1 is a generalized disorder of glu-
cose metabolism that is generally attributed to an absence of
insulin secretion. The unique treatment remains periodic insulin
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injection, a poor approximation of normal physiological insulin
secretion. While oral administration of insulin is a potentially
attractive option, success at delivery via this route has thus far
been elusive. Insulin, like other peptide- or protein-based drugs,
is degraded in the acidic environment of the stomach and by
proteolytic enzymes, especially in the small intestine. In ad-
dition, epithelial surfaces and chemical characteristics of the
gastrointestinal tract present an effective barrier to the absorp-
tion of insulin (Reis et al. 2002a). Numerous strategies have
been devised to enhance insulin absorption. Nanoparticles as a
drug delivery system have been found to be useful in protecting
and/or prolonging insulin effect (Damge´, Maincent, and Ubrich
2007; Jerry et al. 2001; Mesiha, Sidhom, and Fasipe 2005). In
the nanotechnology field, polymeric biomaterials have been re-
ceived increasing attention, especially gastric and proteolytic
protective polymers.
Alginate is a natural biodegradable polymer that gels in the
presence of divalent cations such as calcium. Alginate gel is
relatively permeable and thus has a low retention capacity of
encapsulated molecules (Gursoy and Cevik 2000). The low re-
tention capacity is due probably to an open pore structure that
depends on the extent of swelling and contraction of the alginate
gel. There have been numerous efforts to control the erosion of
alginate and prolong drug release such as coating with polyca-
tionic polymers or blending alginate with other polymers (Lee
et al. 2003). Dextran sulfate is a biodegradable and biocom-
patible polyanion, with a branched carbohydrate backbone and
negatively charged sulfate groups (Chen, Mohanraj, and Parkin
2003). It has been widely used in pharmaceutical formulations
as an effective matrix material for controling release of drugs
(Janes et al. 2001) or as a stabilizing agent (Tiyaboonchai et al.
2003).
Chitosan is a nontoxic and bioabsorbable natural polysac-
charide, with structural characteristics similar to glycosamino-
glycans (Hari, Chandy, and Sharma 1996). It has been studied
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for the release of several drugs or as a gel coating material as its
polymeric cationic characteristics promote interaction with neg-
atively charged molecules or polymers (Boonsongrit, Mitrevej,
and Mueller 2006). Moreover, chitosan adheres to the mucosal
surface and transiently opens the tight junction between epithe-
lial cells. Finally, most polypeptide drugs such as insulin are
short-lived species in vivo. In contrast, BSA is a stable protein in
vivo (Schechter et al. 2005). BSA has been described as a model
encapsulated drug. In this study, bovine serum albumin (BSA)
was used as coating biomaterial with the intent of prolonging
particle residence in the gastrointestinal tract and to provide pro-
tection of the entrapped insulin from intestinal proteases.
The aim of our study was to prepare and characterize poly-
electrolyte nanospheres that can encapsulate, protect and bio-
logically deliver insulin to intestinal mucosa. Polyelectrolyte
nanospheres were produced through nanoemulsion/dispersion
of alginate-drug solution, followed by triggered in situ gelation
of alginate through instantaneous release of Ca2+ from insol-
uble complex. The nanoparticulate core was then coated with
chitosan and/or albumin. Uncoated (ALG), chitosan-coated algi-
nate (ALG-CHIT) and albumin-chitosan-coated alginate (ALG-
CHIT-BSA) nanospheres were prepared and characterized in
terms of size, chemical and thermal complex interactions, encap-
sulation efficiency, protein integrity after pepsin digestion, and
physiological response following oral delivery in diabetic rats.
MATERIALS AND METHODS
Low viscosity sodium alginate (viscosity of 2% solution at
25◦C, 250 cps), chitosan (50 kDa, 75–85% deacetylated), BSA,
and streptozotocin were purchased from Sigma-Aldrich Chimie
(L’Isle d’Abeau Chesnes, France). Dextran sulfate (5 kDa) and
emulsifier, Span 80, were purchased from Fluka Biochemika
(Buchs, Switzerland). Setacarb calcium carbonate was obtained
from Omya (Orgon, France). Paraffin oil was supplied by Vaz
Pereira (Lisbon, Portugal). Insulin was kindly donated by Hospi-
tais da Universidade de Coimbra (Actrapid Insulin©R from Novo
Nordisk, Bagsvaerd, Denmark). All other chemicals were of
reagent grade or equivalent.
Preparation of Nanospheres
Nanosphere preparation involved formulation of alginate par-
ticles through nanoemulsion dispersion followed by triggered
instantaneous particle gelation (Reis et al. 2002b). A solution
with sodium alginate (2%, w/v) and dextran sulfate as adjuvant
(0.75%, w/v) was prepared by stirring (100 rpm) overnight. In-
sulin was then added and dissolved (100 IU/mL, 10 mL). An
aqueous suspension of ultrafine calcium carbonate (5%, w/v)
was added to previous alginate solution and the dispersion was
emulsified within paraffin oil aided by Span 80 emulsifier (1.5%
v/v) at high speed (1600 rpm). After 15 min, gelation was
induced by addition of 20 mL paraffin oil containing glacial
acetic acid to solubilize calcium dispersed in the alginate nan-
odroplets. After 60 min, an acetate buffer solution (pH 4.5,
United States Pharmacopeia [USP XXVIII]) with dehydrating
solvents (100 mL) was added to the oil-nanoparticle suspension
and nanospheres were recovered by centrifugation (12,500 × g
during 10 min) as previously described (Reis et al. 2006c).
Formulation coating variables were investigated for opti-
mization of nanospheres properties by individually changing the
preparation conditions in the described standard protocol with all
other parameters held constant. All types of polymers and their
concentration except BSA were based on previous works (Reis
et al. 2007; Silva et al. 2006). First-coating strategy included
chitosan coating (volume 100 mL at pH 4.5, 0.03% [w/v]) with
high calcium level (CaCl2 at 1.5%, w/v) applied under magnetic
stirring during 30 min. Then, supernatant with unreacted poly-
mer was removed by vacuum. The other strategy involved an
additional coating of BSA (0.5–2% BSA [w/v] in 100 mL at pH
5.1) applied under magnetic stirring during 30 min. Nanospheres
were frozen in an ethanol bath at −50◦C and lyophilized (Lyph-
lock 6, Labconco, Kansas City, MO, USA) at 0◦C for 48 h and
stored at 4◦C without cryoprotectant. These particles were re-
ferred to as dehydrated nanospheres. Insulin-free nanospheres
also were prepared.
Characterization of Nanospheres
Size distribution was determined by laser diffraction spec-
trometry using a Coulter LS130 granulometer (Beckman Coul-
ter, Fullerton, CA, USA). Mean diameters of nanosphere sus-
pensions in acetate buffer pH 4.5 were determined in triplicate.
Polydispersity was expressed as SPAN = [D90% − D10%]/D50%,
where D90%, D10%, and D50% are number size diameters at 90,
10, and 50% of the cumulative number, respectively. A high
value of SPAN indicates a wide distribution in size and a high
polydispersity. The shape of the particles also was characterized
using scanning electron microscopy (SEM) (JSM-840, JEOL
Instruments, Tokyo, Japan). Hydrated particles were dried by
spray-drying and then deposited on metal grids using double-
faced adhesive and coated with gold before observation.
Differential Scanning Calorimetry (DSC)
DSC was used to determine a shift of the alginate endothermic
peak or the appearance of exothermic peaks and consequently
detect interactions between ALG-CHIT and ALG-CHIT-BSA.
Thermograms were obtained using a Shimadzu DSC-50 system
(Shimadzu, Kyoto, Japan).
Sodium alginate, chitosan, and BSA were obtained by
lyophilization of aqueous solution of alginate 2% (w/v), aqueous
solution of chitosan 0.03% (w/v) rich in calcium (CaCl2 at 1.5%,
w/v), and aqueous solution of BSA 0.5 to 2% (w/v), respectively.
Physical mixture was prepared by mixing 1:1 of lyophilized
sodium alginate 2% (w/v) with chitosan 0.03% (w/v) rich in cal-
cium (CaCl2at 1.5%, w/v) and then by mixing 1:1 lyophilized
ALG-CHIT with BSA 0.5 to 2% (w/v). Chitosan–alginate
complexes were obtained by adding 5 mL of chitosan solution
0.03% (w/v) and rich in calcium (CaCl2 at 1.5%, w/v) to 5 mL of
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alginate solution 2% (w/v) at pH 4.5 under agitation for 10 min
followed by lyophilization. BSA-chitosan–alginate complexes
were obtained by adding 5 mL of BSA solution 0.5 to 2% (w/v)
at pH 5.1 to 5 mL of chitosan solution 0.03% (w/v) and rich
in calcium (CaCl2 at 1.5%, w/v) with 5 mL of alginate solu-
tion 2% (w/v) at pH 4.5 under agitation for 10 min followed by
lyophilization.
Coated-insulin nanospheres using different BSA concentra-
tions were tested. Dehydrated samples (∼2 mg) were crimped
in a standard aluminium pan and heated from 20 to 350◦C at
a heating rate of 10◦C/min under constant purging of nitro-
gen at 20 mL/min. The characteristic peaks of the melting en-
dotherm and degradating exotherm were recorded. At least du-
plicates were carried out for each batch of sample and the results
averaged.
Fourier Transform Infrared Spectrometry (FT-IR)
Infrared spectra of samples previously analyzed by DSC were
recorded with a JASCO FT/IR-420 spectrophotometer (Mira-
cle, PIKE©R Technologies) using the attenuated total reflection
method. Samples were scanned from 600 to 4000 cm−1 at a
resolution of 4 cm−1.
Encapsulation Efficiency
The encapsulation efficiency was measured by incubating
15 mg of dehydrated nanospheres in 10 mL of sodium cit-
rate (55 mM)/phosphate buffer at pH 7.4 (USP XXVIII) for
1 hr (100 rpm). The pH of 7.4 was applied to produce higher
protonation of insulin and alginate under simulated physio-
logical conditions, and thus achieve low interaction between
both chemical species. After particle dissolution, the mixture
was centrifuged and protein content in supernatant analyzed
by HPLC (Shimadzu, Columbia, MD, USA, LC-2010; where
mobile phase was water (A): acetonitrile (B) with 0.04% triflu-
oroacetic acid with linear gradient B 30% to 40% over 5 min,
flow rate 1.2 mL/min at 25◦C) using reversed-phase column (X-
Terra C-18 column, 5 µm, 4.6 mm × 250 mm from Waters,
USA) with a precolumn (Purospher STAR, RP-18 precolumn,
5 µm, 4 mm × 4 mm from Merck, Germany). Encapsulation
efficiency was determined by insulin released as percentage of
initial amount used in formulation.
In Vitro Release of Insulin
Drug release studies were focused on the release behavior at
gastric and intestinal pH conditions. Lyophilized insulin-loaded
nanospheres (10 mg) were incubated in 10 mL hydrochloric
acid buffer at pH 1.2 (USP XXVIII), under continuous magnetic
stirring (100 rpm, 2 hr) at 37◦C. Samples at appropriate inter-
vals were withdrawn and assayed for protein. Fresh dissolution
medium was added to maintain a constant volume. To simulate
the progress of nanospheres moving from the stomach into the
upper small intestine, the buffer was changed after 2 hr to higher
pH. Nanospheres were centrifuged (12,500 × g, 10 min) then re-
suspended into 10 mL phosphate buffer at pH 6.8 (USP XXVIII),
under continuous magnetic stirring (100 rpm) during 6 hr. Su-
pernatant samples at appropriate intervals were withdrawn and
assayed for protein, then fresh dissolution medium was added
to maintain a constant volume. Experiments were performed in
triplicate and cumulative insulin release expressed as percentage
of initial insulin loading.
Insulin Molecular Integrity
Insulin (µg insulin per mL nanospheres) molecular integrity
was evaluated by HPLC after nanospheres matrix dissolution
with sodium citrate (55 mM)/phosphate buffer at pH 7.4
(USP XXVIII). Insulin was quantified initially and after 2 hr
incubation in simulated gastric fluid containing pepsin at pH
1.2 (USP XXVIII) in a shaking water bath at 37◦C and 100 rpm.
Nanospheres were recovered by centrifugation and transferred
to citrate solution in phosphate buffer 7.4 (USP XXVIII) with
stirring for 1 hr, then aliquots collected, centrifuged, and ana-
lyzed. Phosphate buffer at pH 7.4 was applied to stop enzyme
activity and to promote insulin release. Insulin encapsulated
without pepsin incubation and nonencapsulated insulin served
as reference and assays were conducted in triplicate. Enzyme
resistance was detected by absence or presence of insulin peak
on HPLC chromatogram.
In Vivo Bioassay of Optimized Nanospheres
The animal model chosen was the diabetic induced rat be-
cause it has several advantages over larger animals: easier ma-
nipulation, ability to simultaneously work with large number of
animals, economical reasons, and mainly similarity to human
diabetes histopathology (Lerco et al. 2003). Male Wistar rats
(270 ± 24 g) were housed in a 12–12 hr light-dark cycle, con-
stant temperature environment of 22◦C, relative humidity 55%,
and allowed free access to water and food during acclimati-
zation. Animals received standard laboratory chow diet (UAR,
Villemoisson-sur-Orge, France) and tap water, available ad li-
bitum. All experiments were carried out in accordance with the
European Community Council Directive of November 24, 1986
(86/609/EEC). Diabetes was induced with intravenous injection
of 65 mg/kg streptozotocin in citrate buffer at pH 4.5 as pre-
viously described (Damge´ et al. 1988). Then 10 days after the
treatment, rats with frequent urination, loss of weight and fasting
blood glucose levels higher than 300 mg/dL were included in
experiments. Blood glucose levels were determined by glucose
oxidase/peroxidase method using a glucometer (Accuchek Go,
Roche, Strasbourg, France).
Animals were fasted 12 hr with free access to water and ran-
domized in three groups: formulation (treatment with insulin-
loaded nanospheres) and two controls (treatment with water and
control insulin-free nanospheres). Water was selected as disper-
sion medium and for that reason it was tested as control. Only
optimized nanospheres were administrated orally through a tube
that was attached to a hypodermic syringe and approximately
2 mL of the aqueous dispersion medium was administered. Oral
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TABLE 1
Size (nm) of tested formulations showing the effect of coating material and BSA concentration on D10%, D50%, D90%, and SPAN
Formulation Parameter D10% D50% D90% SPAN
Dehydrated ALG nanospheres ALG 358 564 1067 1.26
Dehydrated ALG-CHIT nanospheres 0.03% chitosan 741 1280 2652 1.49
Dehydrated ALG-CHIT-BSA nanospheres 0.5% BSA 110a 144a 392a 1.96
1% BSA 110a 144a 298a 1.31
1.5% BSA 110a 158a 298a 1.19
2% BSA 110a 158a 298a 1.19
Hydrated ALG-CHIT-BSAnanospheres 1% BSA 392 677 1402 1.49
aHigh agglomeration.
dosage was 50 IU/kg of animal body weight. Optimized formu-
lation was tested in dehydrated state and in the freshly prepared
hydrated state. Blood samples were taken from the tip of the tail
vein and blood-glucose curve was plotted.
Statistical Analysis
Data are presented as means ± standard error of mean (SEM).
Statistical evaluation was performed with a one-way ANOVA
followed by a Dunnett multiple comparison test. A p < 0.05
was taken as the criterion of significance.
RESULTS
Characterization of Nanospheres
Nanospheres were prepared by nanoemulsion dispersion/
in situ triggered gelation resulting in an unimodal size distri-
bution. Diameter values expressed in number distribution of
nanospheres prepared using different formulation variables are
presented in Table 1, as well as the SPAN factor, a measure of
polydispersivity.
Approximately 50% of ALG and ALG-CHIT nanospheres
showed a diameter of less than 564 and 1280 nm, respectively.
SPAN factor values were 1.26 and 1.49 for ALG and ALG-
CHIT nanospheres. ALG-CHIT-BSA nanospheres showed sub-
stantially lower particle sizes compared with ALG-CHIT and
ALG nanospheres. An increasing concentration of BSA did not
change the diameter. In contrast, the SPAN factor decreased with
increasing concentration of BSA. ALG-CHIT nanospheres were
regular and mainly spherical in shape as shown in Figure 1a)
but coating with BSA resulted in particle shrinkage (Figure 1b)
which is in agreement with size analysis.
DSC Analysis
DSC was used to characterize the polyelectrolyte complex in-
teractions involving alginate, chitosan and BSA. Figure 2 shows
broad and early endothermic peaks of BSA around 70◦C and
220◦C whereas exothermics peaks were localized at 320 and
370◦C. When BSA was mixed with ALG-CHIT complexes, its
spectra changed significantly as shown in Figure 3a and b):
a broad endothermic peak between 60–70 and a new peak at
150◦C that can be attributed to a strong interaction between
polyelectrolytes with intensity increasing with increase of BSA.
The exothermic peak of the ALG-CHIT complex was around
FIG. 1. SEM microphotographs of ALG-CHIT with 0.03% of chitosan
(a) and ALG-CHIT-BSA nanospheres with 1% of BSA (b) (magnification
5000 ×, bars = 10 µm).
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FIG. 2. Thermograms of dehydrated (a) 0.5%, (b) 1%, (c) 1.5%, and (d) 2% BSA.
FIG. 3. Thermograms of dehydrated (a) ALG-CHIT complexes with 0.03% of chitosan and 2% of alginate; (b) ALG-CHIT-BSA complexes with 0.5% BSA;
(c) ALG-CHIT-BSA complexes with 1% BSA; (d) ALG-CHIT-BSA complexes with 1.5% BSA; (e) ALG-CHIT-BSA complexes with 2% BSA.
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132 C. P. REIS ET AL.
FIG. 4. Thermograms of dehydrated (a) physical mixture 1:1 of chitosan and alginate, (b) physical mixture 1:1 of ALG-CHIT complexes with 0.5% BSA,
(c) 1%, (d) 1.5%, and (e) 2% BSA.
334◦C but was not observed on ALG-CHIT-BSA complexes.
In Figure 4, physical mixtures showed slightly different spectra
from polyelectrolyte complexes. The first endothermic peak at
53.5◦C of ALG-CHIT complex changed to 57.3◦C and its in-
tensity increased with BSA concentration and second endother-
mic peak at 236◦C varied from 229.8 to 239◦C depending on
the BSA concentration as shown in Figure 4. A similar effect
was observed for an additional endothermic peak at 85.1◦C. As
illustrated in Figure 5, ALG nanospheres showed characteris-
tic endothermic (63◦C) and exothermic alginate peaks (259◦C).
When chitosan was added, spectra demonstrated two separated
endothermic peaks, at approximately 76◦C and 162◦C and an
exothermic peak around 266◦C. ALG-CHIT-BSA nanospheres
showed different spectra where peaks at 162◦C and 266◦C were
not observed and once again an increase of BSA led to more
pronounced endothermic peaks.
FT-IR Analysis
Table 2 shows the most pronounced peaks of each sample in
the range 1000 to 2000 cm−1. Alginate showed three peaks: 1599
cm−1 corresponding to C O asymmetric stretching, 1410 cm−1
to C O symmetric stretching, and C O stretching at 1029 cm−1.
Chitosan showed two peaks on amide I region at 1696 cm−1
and 1637 cm−1; one peak at amide II region at 1543 cm−1
corresponding to N-H group, and finally 1409 cm−1 to C N
stretching. When chitosan was mixed with alginate, its amide I
peaks shifted from 1696 cm−1to 1692 cm−1and from 1637 cm−1
to 1633 cm−1; and its amide II band changed from 1543 cm−1to
1549 cm−1with large shoulder corresponding to carbonyl group
of alginate. Alginate characteristic peaks at 1410 cm−1 and 1029
cm−1 shifted after chitosan complexation to 1408 cm−1 and
1022 cm−1, respectively. Physical mixture 1:1 of alginate and
chitosan showed a different spectrum compared with polyelec-
trolyte complexes especially C O group at 1592 cm−1. ALG
nanospheres showed a broad band with peaks at 1548, 1409,
and 1029 cm−1whereas the CHIT-ALG nanospheres spectrum
showed small peak carbonyl group at 1617 cm−1, a strong peak
of the amine group at 1540 cm−1, and two more peaks at 1410
and 1019 cm−1.
FT-IR analysis was difficult in the presence of BSA because
the noise during analysis was higher. BSA characteristic peaks
include 1643–1645 and 1534–1547 cm−1corresponding to
amides band I and II, respectively. When BSA was added to
ALG-CHIT complexes, new peaks appeared around 1544–1563
and 1455–1458 cm−1. Spectra of physical mixtures were
different from isolated polyelectrolytes. BSA-coating led to
different spectra showing only a strong dual peak at 1525–1538
and 1559 cm−1.
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FIG. 5. Thermograms of dehydrated loaded (a) ALG nanospheres, (b) ALG-CHIT nanospheres, (c) ALG-CHIT-BSA nanospheres with 0.5%, (d) 1%, (e) 1.5%,
and (f) 2% BSA.
Encapsulation Efficiency
Values of encapsulation efficiency varied from 31 to 90%
for the different formulations as seen in Table 3. They were
particularly affected by coating parameters (p < 0.001). Also,
there was no apparent difference between the efficiency values
for ALG and CHIT-ALG nanospheres. Encapsulation efficiency
decreased with an increase of BSA concentration.
In Vitro Release of Insulin
Figure 6 shows release profiles of insulin from nanospheres
under simulated gastrointestinal conditions. At low gastric pH,
FIG. 6. Release behavior of insulin nanospheres under physiological conditions: ALG (−), ALG-CHIT (––), and ALG-CHIT-BSA nanospheres (––). Each
value represents mean ± S.D. (n = 3).
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TABLE 2
FT-IR analysis of spectra of all tested samples by DSC technique
C O C O symmetric
C O N H asymmetric N H stretching or C O
Compound Amide I Amine stretching Amide II C N stretching
Alginate at 2% (w/v) 1599 1410 1029
Chitosan 0.03% (w/v) rich in calcium 1696 1637 1543 1409
BSA 0.5% (w/v) 1645 1547
BSA 1% (w/v) 1646 1534
BSA 1.5 % (w/v) 1646 1547
BSA 2% (w/v) 1643 1534
Chitosan–alginate complexes 1692 1633 1549 1408 1022
BSA-chitosan–alginate complexes 0.5% (w/v) 1654 1563 1530 1530
BSA-chitosan–alginate complexes 1% (w/v) 1655 1633 1544 1534
BSA-chitosan–alginate complexes 1.5% (w/v) 1655 1642 1554 1541 1455
BSA-chitosan–alginate complexes 2% (w/v) 1680 1642 1538 1458
Physical mixture chitosan–alginate 1692 1633 1592 1558 1409 1025
Physical mixture chitosan–alginate+ BSA 0.5% (w/v) 1650 1559
Physical mixture chitosan–alginate + BSA 1% (w/v) 1650 1559
Physical mixture chitosan–alginate +BSA 1.5% (w/v) 1654 1543
Physical mixture chitosan–alginate + BSA 2% (w/v) 1646 1540 1451
ALG nanospheres 1548 1409 1029
Chitosan-coated nanospheres 1617 1540 1410 1019
ALG-CHIT-BSA nanospheres, BSA 0.5% (w/v) 1559 1538
ALG-CHIT-BSA nanospheres, BSA 1% (w/v) 1559 1525
ALG-CHIT-BSA nanospheres, BSA 1.5% (w/v) 1620 1530
ALG-CHIT-BSA nanospheres, BSA 2% (w/v) 1559 1538
insulin was fully retained in ALG and ALG-CHIT nanospheres
but to a lesser extent with ALG-CHIT-BSA nanospheres. Up
to 70%, 40%, and 40% of the insulin was released almost im-
mediately after changing the medium to near neutral pH for
TABLE 3
Encapsulation efficiency (%) and drug content (%, w/w) of all
insulin formulations
Drug
Encapsulation content
Formulation Parameter efficiency insulin
Dehydrated ALG
nanospheres
— 89.9 ± 3.2 2.44 ± 0.01
Dehydrated
ALG-CHIT
nanospheres
0.03% of
chitosan
82.1 ± 5.9 2.23 ± 0.02
Dehydrated
ALG-CHIT-BSA
nanospheres with
0.03% of chitosan
0.5% of BSA 66.3* ± 5.2 1.82 ± 0.01
1% of BSA 62.8* ± 1.6 1.71 ± 0.03
1.5% of BSA 30.9* ± 1.8 0.84 ± 0.02
2% of BSA 38.5* ± 0.6 1.06 ± 0.05
Each data point represents the mean ± SD from n = 3.
∗Significant difference from ALG and ALG-CHIT nanospheres: p <
0.01.
ALG, ALG-CHIT, and ALG-CHIT-BSA nanospheres, respec-
tively. ALG-CHIT and ALG-CHIT-BSA nanospheres demon-
strated a controlled insulin profile release in simulated intestinal
conditions. Full insulin release was only observed with ALG
nanospheres after 1 hr.
Insulin Molecular Integrity
To examine the protective ability of the ALG, CHIT-ALG,
and ALG-CHIT-BSA nanospheres in the harsh gastric envi-
ronment, insulin-loaded nanospheres were exposed to pepsin
and low pH, and extracted insulin run on HPLC. Nonencap-
sulated insulin was immediately degraded in the presence of
pepsin as seen in Figure 7E. ALG (Figure 7F) and CHIT-ALG
nanospheres (Figure 7G) did not protect insulin from peptic di-
gestion as the protein peak was eliminated. Only nanospheres
with 0.5% (Figure 7H) and 1% (Figure 7I) BSA coating re-
leased intact insulin following pepsin exposure. Insulin peak ap-
peared consistent with intact insulin released from nanospheres
and without pepsin incubation as seen in Figure 7D. In con-
trast, nanospheres with higher levels of BSA coating as seen in
Figures 7J and 7K did not release intact insulin and BSA chro-
matogram zone was gradually degraded with BSA concentration
increase.
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FIG. 7. HPLC curves (a) nonencapsulated insulin, (b, c) insulin encapsulated and released from ALG and ALG-CHIT nanospheres without pepsin incuba-
tion, (d) insulin encapsulated and released from ALG-CHIT-BSA nanospheres without pepsin incubation, (e) nonencapsulated insulin after pepsin incubation,
(f) insulin encapsulated and released from ALG nanospheres after pepsin incubation, (g) insulin encapsulated and released from ALG-CHIT nanospheres after
pepsin incubation, (h) insulin encapsulated and released from ALG-CHIT-BSA nanospheres with 0.5%, (i) 1%, (j) 1.5%, and finally (k) 2% BSA after pepsin
incubation. Insulin retention time at 5 min and BSA retention time ∼7 min. Additive of commercial insulin is represented by single peak at 8.3 min. This additive
is lost after encapsulation and recovery process.
In Vivo Bioassay
Potential use of hydrated and dehydrated nanospheres for
oral delivery and its pharmacological effects were evaluated in
diabetic rats. Nanospheres formulated of alginate and coated
with chitosan and then 1% BSA were used due to their smaller
size, higher encapsulation efficiency, and in vitro enzymatic
protective properties compared with ALG and CHIT-ALG
nanospheres. The insulin profile release also was important,
but the main objective of this study was to deliver insulin to
the intestine, instantaneously or in a controlled pattern, but as
a bioactive form.
Oral administration of dehydrated insulin-loaded ALG-
CHIT-BSA nanospheres (50 IU/kg) reduced the basal glucose
level to 48% as seen in Figure 8. The first reduction of glycemia
with dehydrated nanospheres was observed between 2 and 4 hr.
Water did not decrease the fasting glycaemia within 8 hr whereas
insulin-free ALG-CHIT-BSA nanospheres demonstrated slight
glycemia decrease especially to 80 and 74% at 6 and 8 hr, re-
spectively. Fasting plasma glucose levels in all groups did not
return to the initial level for any of the conditions tested. The
same assay was performed with hydrated insulin-loaded ALG-
CHIT-BSA nanospheres. In this case, a stronger hypoglycemic
effect to 28% within 12 hr was observed compared with 48% for
dehydrated insulin-loaded ALG-CHIT-BSA nanospheres with
significant differences from the water group (p = 0.0579).
DISCUSSION
Insulin-loaded nanospheres were prepared by nanoemulsion
dispersion/in situ-triggered gelation. Coating was an impor-
tant factor in governing the resulting size and shape of the
nanospheres. With chitosan-coating, molecular interactions be-
tween oppositely charged ALG-CHIT formed larger polymeric
particulate networks and ALG alone or ALG-CHIT formed
spherical nanospheres. However, subsequent BSA coating re-
sults in particle shrinkage. BSA at pH 5.1 was negatively charged
interacting with positively charged chitosan (Takahashi et al.
1990) producing a more compact polymer network. A more
compact matrix may provide a better exclusion of acid and pro-
teases. Increase of BSA concentration did not lead to an increase
in nanosphere diameter. In all cases, particle size was lower than
the critical size necessary to enable gastrointestinal absorption
by M-cells on Peyer’s patches (Norris, Puri, and Sinko 1998;
Saez et al. 2000).
DSC and FT-IR showed complex formation between ALG-
CHIT-BSA. DSC thermograms of ALG-CHIT-BSA complexes
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FIG. 8. Blood-glucose levels following oral administration of hydrated insulin-loaded ALG-CHIT-BSA nanospheres (•, n = 6), dehydrated insulin-loaded
ALG-CHIT-BSA nanospheres (, n = 6), hydrated insulin-free ALG-CHIT-BSA nanospheres (◦, n = 6), dehydrated insulin-free ALG-CHIT-BSA nanospheres
(, n = 6), and water (, n = 8) in diabetic male Wistar rats fasted for 12 hr. The dose of insulin was 50 IU/kg body weight. Each value represents mean ± S.E.M.
*statistically different from water with p < 0.05.
were different from isolated polyelectrolyte and ALG-CHIT
complexes. DSC thermogram of ALG-CHIT-BSA complexes
showed the formation of two endothermic transitions between
50–100◦C and 155◦C, which may have resulted, respectively,
from elimination of water (Smitha, Sridhar, and Khan 2005)
and the formation of interactions in polyelectrolyte complex
structure. ALG-CHIT-BSA interaction can be characterized by
disappearance of the degradation exothermic peak of isolated
BSA. Exothermic peaks are usually associated with dehydra-
tion, depolymerization, and pyrolitic reactions (Zohuriaan and
Shokrolahi 2004).
FT-IR spectra indicates that the peak shifts mainly take place
in absorption bands of amine groups of chitosan, amide of BSA,
and carboxyl acid groups of alginate, demonstrating electro-
static interaction between ALG-CHIT-BSA. For ALG-CHIT
complexes, the asymmetric –C-O- stretching disappeared and a
new broad band with strong peak of amine coupled with amide II
appeared, indicating that NH+3 present in chitosan interacts with
–COO−of alginate. Electrostatic binding resulted between algi-
nate and chitosan, since at working pH, alginate was an anionic
polymer in solution (Murata, Miyamoto, and Kawashima 1996)
and chitosan was a cationic polymer, and the resulting complex
is well documented (Bechera´n-Maro´n, Peniche, and Argu¨elles-
Monal 2004; Gaserod, Smidsrod, and Skjak-Braek 1998; Lee,
Park, and Ha 1997; Sankalia et al. 2006; Tapia et al. 2004).
There are three types of ionic interactions that contribute
to the three-dimensional cross-linked networks of CHIT-ALG
nanospheres: the interaction between opposite charges of the
biopolymers (electrostatic interactions), the junction formed by
the calcium ion, and the guluronic and mannuronic acid units
and interchain hydrogen bonds (Sankalia et al. 2006). In ALG-
CHIT-BSA complexes, interactions occurred not only between
alginate and chitosan, but also between ALG-CHIT and BSA.
Complexes between alginate and BSA also have been described
in the literature. But in those cases, BSA was used as model pro-
tein and not as coating biomaterial (Coppi et al. 2001). These
polyelectrolyte complexes are carrying a relatively large number
of functional groups that either are charged, or under suitable
conditions, can become charged. The formation of polyelec-
trolyte complexes is mainly driven by an electrostatic mecha-
nism. Charge neutralization and possible local overcompensa-
tion or bridging (such as hydrogen bonding, Coulomb forces,
van der Waals forces, and transfer forces) are generally medi-
ated by a multivalent counterion that induces attraction between
segments of the polyelectrolytes (Sankalia et al. 2006).
Insulin can be incorporated into nanospheres with high ef-
ficiency for ALG and CHIT-ALG nanospheres. In both cases,
positive amino groups of insulin (pI=5.3) (Chien 1996) strongly
interact with carboxylic groups of alginate (pKa 3.38 and 3.65)
(Draget et al. 1994). Data suggest that chitosan coating led
to slight decrease of insulin encapsulation efficiency probably
due to some destabilization of alginate structure as alginate
also interacts with chitosan. The data suggest that BSA coat-
ing decreased the encapsulation efficiency of insulin within the
nanospheres. Encapsulation efficiency likely involved an addi-
tional electrostatic interaction between the positively charged
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chitosan and BSA. Thus, it led to an electrostatic competition
between BSA and alginate to chitosan and some insulin could
be forced out during the coating process.
Insulin release from alginate matrices changed with the
choice of coating polymers. First, an absence of insulin release
was observed at low pH with ALG nanospheres. Previous work
demonstrated that the main reason for protein retention was due
to the presence of an addition polyanion in alginate matrix (Silva
et al. 2006). The addition of dextran sulphate as another polyan-
ion to alginate matrix increases the polymer concentration which
may result in a strong network density. But the effect observed
on insulin release at pH 1.2 seemed to be due mainly to elec-
trostatic interactions. Sulfate groups of dextran sulfate will be
permanently charged since they have a negative first pK a value
and a second pK a value near 2. The presence of negative charges
may be responsible for additional interaction with insulin (iso-
electric point, pI = 5.3–5.4) at acidic pH, thus preventing its
release. This retention was only observed at low pH.
When ALG nanospheres were transferred to intestinal fluid,
a complete and fast release of insulin was observed because
the alginic acid formed during acid incubation was converted
to a soluble salt of sodium alginate causing the matrix to swell
and disintegrate. The same low pH profile release was observed
with ALG-CHIT nanospheres. In contrast, when ALG-CHIT
nanospheres were transferred to intestinal fluid, a controlled in-
sulin release was observed. It seems that chitosan may form a
polyelectrolyte complex membrane with alginate possibly serv-
ing as a diffusional barrier. These results are in agreement with
previous studies where chitosan-coating was able to decrease gel
erosion (Murata et al. 1993) allowing sustained release (Polk et
al. 1994; Sezer and Akbuga 1999) from alginate microspheres.
In our study, a different profile release occurred with BSA
coating. Approximately 15% of insulin was released at low pH
and a similar release profile was observed after transfer to pH
6.8. Insulin release at pH 1.2 could be due to an electrostatic
competition between all chemical species involved forcing out
some insulin during the coating process.
The major objective behind the synthesis of nanospheres
was to prepare particles that protected insulin from protease
digestion. ALG nanospheres did not offer adequate protection
from pepsin probably due to high alginate porosity (Quong and
Neufeld 1998). During simulated gastric passage, nanospheres
cross a very acidic microenvironment with high proton concen-
tration. Protons diffuse faster than calcium ions present in al-
ginate calcium gel (Quong et al. 1998) forming alginic acid.
These protons can alter alginate network structure increas-
ing probability of pepsin-inward diffusion. Chitosan-coated
nanospheres should have the advantage of creating an ionic en-
vironment that can favor the stabilization of bioactive agents
such as insulin (Sajeesh and Sharma 2006). Moreover, chitosan
has been described as coating polymer to alter alginate ma-
trix permeability (Quong and Neufeld 1998). Such polyelec-
trolyte nanospheres displayed suitable protein retention but it
provided minimal protease protection, likely because the per-
meability of alginate matrix was not so well modulated by
chitosan.
Intermixing of anionic-cationic–anionic polymers leads to
smaller size that can imply a more compact interpolymer net-
work. Smaller size can restrict the intrinsic mobility of individual
polymer chains and avoid pepsin diffusion. In addition, most
polypeptide drugs, and in particular the nonglycosylated pro-
teins of molecular mass less than 50 kDa such as insulin with
5.8 kDa (Shen and Xu, 2000), are short-lived species in vivo,
having circulatory half-lives of 5–20 min. In contrast, BSA is
described as a stable protein in vivo (Schechter et al. 2005). As in
the release profile mechanism, the precise mechanism of insulin
enzyme resistance remains unclear. But the observed resistance
effect may be due to BSA that serves as degradative target to
pepsin, leaving the encapsulated insulin intact.
Finally, blood-glucose levels decreased gradually with orally
dosed insulin-loaded nanospheres mainly due to the protec-
tive/stabilizing effect of BSA coating. As BSA should be largely
degraded in the stomach, the coating on nanospheres being trans-
ported into the intestine may begin to break down, initiating the
release of entrapped insulin. Oral hypoglycemic effect appeared
after 12 hr likely due to the delayed release of insulin following
BSA digestion. Also, in this study insulin-free nanospheres had
a slight hypoglycemic effect probably because many viscous
soluble polysaccharides have been correlated with hypocholes-
terolemic and hypoglycaemic effects (Burting 2003) and this
may be the case of alginate (Ohta et al. 1997). Chitosan also
has been used as a hypocholesterolemic and hypoglycaemic
agent (Hasegawa et al. 2001) and may be responsible for hy-
poglycemic effect observed in diabetic rats. Finally, hydrated
nanospheres showed a much stronger hypoglycemic effect than
did dehydrated nanospheres, likely due to differences in insulin
absorption. Some nanosphere agglomeration is expected dur-
ing lyophylization (Donini et al. 2002) delaying insulin release.
Generally, hydrated formulations have an easier dissolution in
contact with physiological fluids (Prista, Alves, and Morgado
1995). Consequently, dissolution time is lower than dehydrated
formulation.
Hydrated nanospheres showed higher particle size than de-
hydrated nanospheres, but even so their size was lower than the
critical size to be captured by Peyer’s patches. As we know, up-
take by Peyer’s patches is particle size dependent (Reis et al.
2002a). Particles captured by Peyer’s patches should have rapid
absorption through the lymphatic system and may avoid prehep-
atic metabolism. At target tissue, for the same time of action,
hydrated nanospheres demonstrated a stronger hypoglycemic
effect probably due to easier contact with intestinal mucosa. In
future work, the hydrated formulation will be subject to further
studies to examine nanosphere intestinal absorption.
CONCLUSION
Polyelectrolyte nanospheres show potential as an oral dosage
system for insulin and potentially other protein-based drugs.
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Insulin nanospheres demonstrated an encapsulation efficiency
from 31 to 85% and unimodal size distribution. Generally,
50% of nanospheres have particle size less than 564, 1280,
and 144–158 nm for ALG, CHIT-ALG, and ALG-CHIT-BSA
nanospheres, respectively. The choice of coating polymer seems
to influence insulin release profile and to be crucial to prevent
peptic digestion. Only ALG-CHIT-BSA nanospheres with 0.5%
and 1% BSA were able to protect and preserve protein stability
during pepsin incubation. Optimized formulation consisting of
ALG-CHIT-BSA nanospheres with 1% BSA was orally admin-
istered to diabetic rats showing a glucose reduction to 48% of
initial value within 12 hr. Same formulation but in hydrated state
showed higher glucose reduction to 28% of initial value within
the same period. ALG-CHIT-BSA nanospheres appear to be a
promising delivery vehicle for oral insulin therapy.
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